To enhance the effectiveness of BRAF inhibitors and delay resistance, they are often used in combination with other targeted therapies, such as MEK inhibitors. This combination has shown improved outcomes in clinical trials, offering a more comprehensive blockade of the cancer's signaling pathways.
